FRED血流导向装置:连续50例患者的安全性与有效性研究
连续纳入50例(52个动脉瘤)宽颈、泡状或梭形/夹层动脉瘤患者,置入54枚FRED(20例联合弹簧圈)。装置置入全部成功,无装置相关并发症及治疗相关死亡;3个月完全闭塞率72.3%,6个月完全及瘤颈残余闭塞率87.2%(单纯FRED组81.5% vs 联合治疗组95.0%)。作者认为FRED治疗各类脑动脉瘤安全,3、6个月闭塞率高,与其他血流导向装置相当。
要点
- 3个月完全闭塞率72.3%,6个月完全及瘤颈残余闭塞率87.2%。
- 6个月闭塞率单纯FRED组81.5% vs 联合弹簧圈组95.0%。
- 无装置相关并发症及治疗相关死亡,1例轻度卒中症状数日内完全消退。
核心结论
- FRED血流导向装置治疗各类脑动脉瘤安全,3个月和6个月闭塞率高,与其他血流导向装置相当,长期闭塞率可期。
研究设计与样本
- 连续病例系列,50例患者、52个动脉瘤,置入54枚FRED,其中20例联合弹簧圈治疗;纳入宽颈、泡状或梭形/夹层动脉瘤(不限大小),治疗时间为2014年2月至2015年5月;3个月用平板CT、6个月用DSA评估,采用Raymond分类和O'Kelly-Marotta分级。
诊断标准与关键数值
- 3个月平板CT随访示整体研究组完全闭塞率72.3%。
- 6个月DSA随访示完全及瘤颈残余闭塞率87.2%,单纯FRED组81.5% vs 联合治疗组95.0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Endovascular flow diverters are increasingly used for the treatment of cerebral aneurysms. We assessed the safety and efficacy of the Flow-Redirection Endoluminal Device (FRED) in a consecutive series of 50 patients.
MATERIALS AND METHODS: Inclusion criteria were wide-neck, blister-like, or fusiform/dissecting aneurysms independent of size, treated with the FRED between February 2014 and May 2015. Assessment criteria were aneurysm occlusion, manifest ischemic stroke, bleeding, or death. The occlusion rate was assessed at 3 months with flat panel CT and at 6 months with DSA by using the Raymond classification and the O'Kelly-Marotta grading scale.
RESULTS: Fifty patients with 52 aneurysms were treated with 54 FREDs; 20 patients were treated with the FRED and coils. Aneurysm size ranged from 2.0 to 18.5 mm. Deployment of the FRED was successful in all cases. There were no device-associated complications. One patient developed mild stroke symptoms that fully receded within days. There have been no late-term complications so far and no treatment-related mortality. Initial follow-up at 3 months showed complete occlusion in 72.3% of the overall study group, Six-month follow-up showed total and remnant-neck occlusion in 87.2% of patients, distributed over 81.5% of the FRED-only cases and 95.0% of the cases with combined treatment.
CONCLUSIONS: The FRED flow diverter is a safe device for the treatment of cerebral aneurysms of various types. Our data reveal high occlusion rates at 3 and 6 months, comparable with those in other flow diverters. Long-term occlusion rates are expected.
引用
- Luecking H, Engelhorn T, Lang S, et al. FRED Flow Diverter: A Study on Safety and Efficacy in a Consecutive Group of 50 Patients. AJNR Am J Neuroradiol. 2017. PMID: 28104636. doi:10.3174/ajnr.A5052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。